PROTECTHEALTH STRENGTHENS GOVERNANCE AND SERVICE CONTINUITY WITH ISO 22301 BCMS CERTIFICATION

by | PRNewswire Asia

CYBERJAYA, Malaysia, March 4, 2026 /PRNewswire/ — ProtectHealth Corporation Sdn. Bhd. has reinforced its role as a key government agency and strategic purchaser of healthcare services with the successful attainment of the ISO 22301:2019/AMD1:2024 Business...

Antengene and UCB Enter Global License Agreement for ATG-201, a CD19/CD3 Bispecific T-Cell Engager for Autoimmune Diseases

by | PRNewswire Asia

Antengene grants UCB worldwide exclusive rights to develop, manufacture and commercialize ATG-201, a CD19/CD3 bispecific T-cell engager (TCE) antibody, targeting B cell-related autoimmune diseases. Antengene will receive USD 80 million of upfront and near-term...

Hon Hai Technology Group (Foxconn) Commits To New 5-Year Sustainability Roadmap Through 2030

by | PRNewswire Asia

TAIPEI, March 3, 2026 /PRNewswire/ — Hon Hai Technology Group ("Foxconn") (TWSE:2317) today announced ambitious sustainability targets through 2030 that focus the next five years on clean energy, labor rights, supply chain ESG and global...

Senhwa Biosciences Signs Major Strategic MOU with Y Combinator-Backed AI Biotech Company CellType to Accelerate the Evolution of CX-4945 into Version 2.0 and Reshape the Global Immunotherapy Landscape

by | PRNewswire Asia

TAIPEI and SAN DIEGO, March 3, 2026 /PRNewswire/ — Senhwa Biosciences, Inc. (TPEx: 6492), a clinical stage company focusing on development of first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced the signing of a major...

Rosti Asia 2025 Review & 2026 Outlook: Building on Shared Success

by | PRNewswire Asia

SINGAPORE, March 3, 2026 /PRNewswire/ — A report from Ringiertrade. Pat Williams, Senior Vice President of Rosti Asia, writes how Rosti Asia has performed strongly across its markets in 2025 despite challenges, as it looks forward to new opportunities in 2026....

Hua Medicine Announces the Approval of Dorzagliatin for Marketing in Hong Kong SAR, China

by | PRNewswire Asia

First glucokinase-activator (GKA) approval outside mainland China Approval supports a differentiated approach to Type 2 diabetes (T2D) management Hong Kong will serve as Hua Medicine’s launchpad for international market expansion SHANGHAI and HONG...